Molecular Pharmacology (USA), Accounts Payable

The latest accounts payable for MLPH is $32K as of September 2014. That compares with $34K in the prior-year period — down 7.0% year over year. Investors often review this figure alongside Molecular Pharmacology (USA),'s historical trend and sector peers before judging valuation or financial health.

Over the past year, MLPH's accounts payable moved from $34K to $32K — a 7.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Molecular Pharmacology (USA),'s operating scale or balance-sheet position.

A accounts payable figure of $32K for MLPH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MLPH's accounts payable ($32K), review year-over-year change from $34K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.